Eugenia Resmini

Eugenia Resmini

Auto-generated profile, based on publicly available information

Eugenia Resmini

Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2009 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
EREugenia Resmini
Eugenia Resmini
FMFrancesco Minuto
Francesco Minuto
ACAnnamaria Colao
Annamaria Colao
DFDiego Ferone
Diego Ferone

28 May 2015 in Endocrine
Verified
Journal Article
Closed access
PDF file
ICIris Crespo
Iris Crespo
ASAlicia Santos
Alicia Santos
EVElena Valassi
Elena Valassi
PPPatricia Pires
Patricia Pires
SWSusan M Webb
Susan M Webb
EREugenia Resmini
Eugenia Resmini

1 June 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
EREugenia Resmini
Eugenia Resmini
APAndrea Parodi
Andrea Parodi
VSVincenzo Savarino
Vincenzo Savarino
AGAlfredo Greco
Alfredo Greco
ARAlberto Rebora
Alberto Rebora
DFDiego Ferone
Diego Ferone
Context: Gastrointestinal abnormalities in acromegaly include dolichomegacolon, slow colonic transit, and increased prevalence of colonic polyps. Conversely, no data are available on the small intestine. Objective: The aim of the study was to investigate the orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO). Patients: A total of 41 acromegalic patients and 30 sex- and age-matched control subjects entered the study. Acromegalic patients were classified according to the medical treatment with somatostatin analogs as “treated” (n = 22) and “untreated” (n = 19), whereas according to the disease control, as “controlled” (n = 17), “uncontrolled” (n = 10), and “partially controlled” (n = 14). Patients and controls completed a questionnaire and underwent a standardized 10-g lactulose hydrogen breath test to determine the OCTT and presence of SIBO. SIBO-positive patients underwent eradication with rifaximine. Results: An increased prevalence of SIBO (18 of 41 vs. 1 of 30; P < 0.0001) and a significantly delayed OCTT (169.53 ± 8.15 vs. 107.25 ± 6.56 min; P < 0.0001) were evidenced in patients compared with controls. No significant statistical differences were found between “treated” or “untreated” patients positive for SIBO or between “controlled,” “partially controlled,” and “uncontrolled” patients. OCTT was significantly delayed in “treated” vs. “untreated” patients (183.21 ± 9.01 and 158.89 ± 6.38, respectively; P = 0.02) and in patients compared with controls (105.75 ± 6.34; P < 0.0001). Rifaximine eradicated SIBO in more than 50% of patients who underwent treatment. Conclusions: These data demonstrate for the first time that SIBO occurs more frequently in acromegalic patients, however, it can be successfully treated by a specific antibiotic. Medical therapy with somatostatin analogs does not affect SIBO prevalence. OCTT resulted significantly prolonged in both “treated” and “untreated” patients, suggesting that acromegaly determines per se an impairment of the intestinal motility. Indeed, disease control seems irrelevant on the delayed OCTT, suggesting that this alteration might be an irreversible complication of acromegaly, probably related to an autonomic intestinal disorder, as we have previously demonstrated at the cardiac level.

22 June 2004 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
FMFrancesco Minuto
Francesco Minuto
EREugenia Resmini
Eugenia Resmini
MBMara Boschetti
Mara Boschetti
MAMarica Arvigo
Marica Arvigo
MSMaria Pia Sormani
Maria Pia Sormani
ABAntonina Barreca
Antonina Barreca

1 July 2014 in European Journal of Endocrinology
Verified
Journal Article
Open access
AAAnna Aulinas
Anna Aulinas
MRMaría-José Ramírez
María-José Ramírez
MBMaria-José Barahona
Maria-José Barahona
EVElena Valassi
Elena Valassi
EREugenia Resmini
Eugenia Resmini
SWSusan M Webb
Susan M Webb
Introduction: Hypercortisolism in Cushing's syndrome (CS) is associated with increased morbidity and mortality. Hypercortisolism also occurs in chronic depressive disorders and stress, where telomere length (TL) is shorter than in controls. We hypothesized that shortening of telomere might occur in CS and contribute to premature aging and morbidity.Aim: To investigate TL in CS patients compared with controls.Methods: Seventy-seven CS patients (14 males, 59 pituitary, 17 adrenal, and one ectopic; 21 with active disease) were compared with 77 gender-, age-, and smoking-matched controls. Fifteen CS were evaluated longitudinally, during active disease and after remission of hypercortisolism. Leukocyte TL was measured by telomere restriction fragment–Southern technique. Clinical markers were included in a multiple linear regression analysis to investigate potential predictors of TL.Results: Mean TL in CS patients and controls was similar (7667 vs 7483 bp, NS). After adjustment for age, in the longitudinal evaluation, TL was shorter in active disease than after remission (7273 vs 7870, P<0.05). Age and dyslipidemia were negative predictors (P<0.05), and total leukocyte count was a positive predictor for TL (P<0.05). As expected, a negative correlation was found between TL and age (CS, R=−0.400 and controls, R=−0.292; P<0.05). No correlation was found between circulating cortisol, duration of exposure to hypercortisolism or biochemical cure and TL.Conclusion: Even though in the cross-sectional comparison of CS and controls no difference in TL was found, in the longitudinal evaluation, patients with active CS had shorter TL than after biochemical cure of hypercortisolism. These preliminary results suggest that hypercortisolism might negatively impact telomere maintenance. Larger studies are needed to confirm these findings.

10 September 2008 in Journal of Andrology
Verified
Journal Article
Closed access
EREugenia Resmini
Eugenia Resmini
GAGabriella Andraghetti
Gabriella Andraghetti
ARAlberto Rebora
Alberto Rebora
RCRenzo Cordera
Renzo Cordera
LVLara Vera
Lara Vera
DFDiego Ferone
Diego Ferone